RNS 60

Drug Profile

RNS 60

Alternative Names: Oxygenated saline; RNS60

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revalesio
  • Developer Massachusetts General Hospital; Revalesio; Rush University
  • Class Anti-inflammatories; Antiasthmatics; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action G protein-coupled receptor modulators; HSP90 heat-shock protein modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Multiple sclerosis
  • Phase I Amyotrophic lateral sclerosis; Myocardial infarction
  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 07 Dec 2016 Revalesio Corporation plans a phase II trial for Amyotrophic lateral sclerosis in USA (Inhalation) (NCT02988297)
  • 20 Oct 2016 CTP push 258609 (NCT02497222) - trial withdrawn
  • 03 Oct 2016 Revalesio withdraws a phase II trial prior to enrolment in Asthma in USA (NCT02497222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top